Allergy Therapeutics plc (AIM: AGY), the specialist pharmaceutical company focused on allergy vaccination, announces that it has commenced dosing in patients in its pivotal Phase III ragweed allergy trial (R301). This trial will be undertaken at more than 65 centres in the United States and Canada.
